These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20145158)

  • 21. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
    Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
    Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
    Ma J; Gao W; Gao J
    Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
    Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
    Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clusterin, a Novel DEC1 Target, Modulates DNA Damage-Mediated Cell Death.
    Ming X; Bao C; Hong T; Yang Y; Chen X; Jung YS; Qian Y
    Mol Cancer Res; 2018 Nov; 16(11):1641-1651. PubMed ID: 30002194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
    Huang H; Wang L; Li M; Wang X; Zhang L
    World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
    Tang Y; Liu F; Zheng C; Sun S; Jiang Y
    J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells.
    Wang Q; Cao W; Su Q; Liu Z; Zhang L
    World J Surg Oncol; 2014 Apr; 12():124. PubMed ID: 24767179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
    Zhang B; Liu ZM; Hao FG; Wang M
    Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
    Ma G; Cai H; Gao L; Wang M; Wang H
    World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
    Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
    Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
    Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
    J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer.
    Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X
    Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein.
    Criswell T; Klokov D; Beman M; Lavik JP; Boothman DA
    Cancer Biol Ther; 2003; 2(4):372-80. PubMed ID: 14508108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
    Muhammad LA; Saad F
    Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect.
    Klokov D; Leskov K; Araki S; Zou Y; Goetz EM; Luo X; Willson D; Boothman DA
    Oncogene; 2013 Jan; 32(4):479-90. PubMed ID: 22391565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects.
    Klokov D; Criswell T; Leskov KS; Araki S; Mayo L; Boothman DA
    Mutat Res; 2004 Dec; 568(1):97-110. PubMed ID: 15530543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.